Edition:
United States

Titan Pharmaceuticals Inc (TTNP.OQ)

TTNP.OQ on NASDAQ Stock Exchange Capital Market

1.38USD
12 Dec 2017
Change (% chg)

$-0.12 (-8.33%)
Prev Close
$1.50
Open
$1.50
Day's High
$1.50
Day's Low
$1.38
Volume
29,366
Avg. Vol
30,097
52-wk High
$4.75
52-wk Low
$1.30

Chart for

About

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery... (more)

Overall

Beta: 2.12
Market Cap(Mil.): $28.63
Shares Outstanding(Mil.): 21.20
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.83 15.71
EPS (TTM): -- -- --
ROI: -- 15.03 31.93
ROE: -- 16.54 16.16

BRIEF-Titan Pharmaceuticals Says Co​ Entered Into A Binding Term Sheet With L. Molteni & C. Dei F.Lli Alitti Societ*I Esercizio

* TITAN PHARMACEUTICALS INC - ON NOV 27, CO​ ENTERED INTO A BINDING TERM SHEET WITH L. MOLTENI & C. DEI F.LLI ALITTI SOCIET*I ESERCIZIO - SEC FILING

Nov 28 2017

BRIEF-Titan Pharmaceuticals Partners With Molteni To Market Probuphine In Europe

* TITAN PHARMACEUTICALS PARTNERS WITH MOLTENI TO MARKET PROBUPHINE® IN EUROPE

Nov 28 2017

CORRECTED-BRIEF-European Medicines Agency Accepts Titan's Marketing Application For Probuphine

* EUROPEAN MEDICINES AGENCY ACCEPTS TITAN PHARMACEUTICALS' MARKETING AUTHORIZATION APPLICATION FOR PROBUPHINE®

Nov 27 2017

BRIEF-Titan Pharmaceuticals reports Q3 loss per share of $0.20

* Titan pharmaceuticals reports third quarter 2017 financial results

Nov 09 2017

BRIEF-Titan Pharmaceuticals files for offering of up to 280,612 shares by selling stockholder

* Titan Pharmaceuticals Inc files for offering of up to 280,612 shares of co's common stock by the selling stockholder - SEC filing‍​ Source text:[http://bit.ly/2izOUEZ] Further company coverage:

Oct 26 2017

BRIEF-Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

* Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

Oct 02 2017

BRIEF-Opiant Pharma, Titan Pharmac to explore new treatments for opioid abuse

* Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

Oct 02 2017

BRIEF-Titan Pharma receives FDA clearance to begin clinical study of Parkinson's disease treatment

* Titan Pharmaceuticals receives fda clearance to begin clinical study of Parkinson's disease treatment Source text for Eikon: Further company coverage:

Aug 24 2017

BRIEF-Titan Pharmaceuticals Q2 loss per share $0.16

* Titan Pharmaceuticals reports second quarter 2017 financial results

Aug 09 2017

BRIEF-Titan Pharmaceuticals secures $10 mln debt facility from Horizon Technology Finance

* Titan Pharmaceuticals secures $10 million debt facility from Horizon Technology Finance

Jul 27 2017

Earnings vs. Estimates